The biotech landscape is ever-evolving, with companies frequently facing the challenge of adapting to the unexpected. This week, a number of notable shifts have been observed in the industry, including strategic pivots and acquisitions that have put a spotlight on the rapidly shifting terrain of biopharmaceutical development.
Keros Therapeutics, a leader in the development of innovative therapies for severe disorders, has announced a strategic restructuring that involves halting its top pulmonary arterial hypertension drug, cibotercept. The decision was made following some concerning observations in a Phase 2 study, where participants exhibited a potentially dangerous fluid buildup post-administration of the drug. In response, the company has decided to lay off 45% of its staff, translating to a projected annual savings of $17 million. Although the situation presents a setback, Keros remains undeterred, planning to reassess its development strategy for cibotercept and its other programs, signaling resilience in the face of adversity.
Meanwhile, on the international front, Astellas Pharma has acquired a stake in a China-based biotech company specializing in Antibody-Drug Conjugates (ADCs). This move highlights Astellas’ recognition of the potential of ADCs, a potent class of therapeutics, and the increasing importance of the Chinese market in global biopharmaceutical innovation.
A noteworthy shift has also been observed at PepGen. The company has decided to pivot its focus from Duchenne muscular dystrophy to myotonic dystrophy type 1 after disappointing early-stage results from its oligonucleotide drug. Despite the setback, initial data on the new treatment for myotonic dystrophy offers a ray of hope, suggesting that success may still be on the horizon for the company. Stifel analyst Paul Matteis, however, alerted investors to the skepticism surrounding the Duchenne drug, which led to a decline in PepGen’s market value post-IPO in 2022.
In other news, Stealth Biotherapeutics and Taysha Gene Therapies also faced their share of challenges. The FDA rejected a drug developed by Stealth for Barth syndrome but provided a potential path to secure an accelerated approval, focusing on the drug’s effects on muscle strength as an “intermediate clinical endpoint.” Stealth plans to submit existing data as part of a new application, but will reduce its workforce by 30% to conserve cash for the upcoming review.
These recent developments underscore the dynamic and unpredictable nature of the biotech industry. Even so, they also highlight the perseverance and adaptability of these companies, who continue to push boundaries in their quest for new treatments and cures. The industry continues to watch and learn as these stories unfold, serving as a testament to the complex journey of bringing novel therapies from the laboratory to the patient’s bedside.
Read more from biopharmadive.com
